CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology that was pioneered by Professor John Rose at Yale University School of Medicine and is exclusively licensed by CaroGen for the development and commercialization of VLV immunotherapies worldwide.

Our vision is to create a wave of potentially transformative, first-in-class immunotherapeutics designed to engage the body's immune system to both recognize and fight off infectious diseases and cancer. We are leveraging our VLV platform to develop a portfolio of products against diseases of high unmet need.